<DOC>
	<DOC>NCT00002348</DOC>
	<brief_summary>To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing non-Hodgkin's lymphoma (NHL).</brief_summary>
	<brief_title>A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description>Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter. It is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Mitoguazone</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV positivity by ELISA confirmed by Western blot. AIDSrelated NHL that is refractory or relapsed. Life expectancy of at least 12 weeks. Exclusion Criteria Coexisting Condition: Patients with the following symptoms and conditions are excluded: Concomitant malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or nonactive, nonvisceral Kaposi's sarcoma not requiring active chemotherapy. Active uncontrolled bacterial infection, viral infection (other than herpes simplex), or fungal infection (other than oropharyngeal candidiasis) that requires treatment within 2 weeks of study entry. Significant cardiovascular disease. Concurrent Medication: Excluded: Hormonal therapy (except medications given for muscle wasting, such as testosterone or Megace). Other chemotherapy. Investigational anticancer drugs. Concurrent Treatment: Excluded: Concomitant radiation to sites other than CNS. Patients with the following prior conditions are excluded: Prior malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or nonactive, nonvisceral Kaposi's sarcoma not requiring active chemotherapy. Recommended: Prophylaxis for PCP and oral candidiasis. Required in patients with leptomeningeal disease: Intrathecal methotrexate or cytarabine (AraC). Leucovorin. Required in patients with leptomeningeal disease: Cranial radiation to a helmet field.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Lymphoma, AIDS-Related</keyword>
	<keyword>Mitoguazone</keyword>
</DOC>